Cancer Family
Osteolytic Neoplasm
CI-CAN-00000043Explore in graph →
Non-malignant7 active trials4 evidence items
- NCIt
- C36030
Loading cancer entity…
Cancer Family
CI-CAN-00000043Explore in graph →
Clinical trials
25 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06647901 | Efficacy of ICG-based NIR Imaging in Intralesional Curettage of Giant Cell Tumors of Bone in Limbs: a Prospective, Single-center, Single-arm, Open Study | recruiting | Phase 1 / Phase 2 | 45 | Tang XiaodongOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT05595603 | Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage | recruiting | Phase 2 | 153 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 15, 2023 | clinicaltrials |
Data updated 22 days agoSource updated May 22, 2026source: clinicaltrials
| NCT00396279 | Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone | completed | Phase 2 | 37 | AmgenINDUSTRY | 0 | Nov 8, 2022 | clinicaltrials |
| NCT04255576 | Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone | unknown | Phase 1 / Phase 2 | 139 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Oct 14, 2022 | clinicaltrials |
| NCT00680992 | Study of Denosumab in Subjects With Giant Cell Tumor of Bone | completed | Phase 2 | 535 | AmgenINDUSTRY | 12 | Sep 22, 2022 | clinicaltrials |
| NCT03620149 | Reduced Dose-density of Denosumab for Unresectable GCTB(REDUCE) | terminated | Phase 2 | 2 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Jan 6, 2021 | clinicaltrials |
| NCT03605199 | Denosumab in Subjects With Giant Cell Rich Tumors of Bone | unknown | Phase 2 | 60 | Leiden University Medical CenterOTHER | 3 | Aug 26, 2019 | clinicaltrials |
| NCT03066245 | Use of Stem Cells Cultured on a Scaffold for the Treatment of Aneurysmal Bone Cysts (ABC) | unknown | Phase 1 / Phase 2 | 4 | Sophia Al-AdwanOTHER | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00464620 | Trial of Dasatinib in Advanced Sarcomas | completed | Phase 2 | 366 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Nov 23, 2018 | clinicaltrials |
| NCT03415477 | Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts(Deno-ABC) | completed | Phase 1 / Phase 2 | 6 | Peking University People's HospitalOTHER | 0 | Jan 30, 2018 | clinicaltrials |
| NCT00889590 | Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)(HR-GCT) | terminated | Phase 2 | 15 | Leiden University Medical CenterOTHER | 2 | Jan 26, 2016 | clinicaltrials |
| NCT01564121 | Study of the Effect of Zoledronate on Local Recurrence After Surgical Treatment of Giant Cell Tumors of Bone Zométa(Zometa) | terminated | Phase 1 / Phase 2 | 24 | Nantes University HospitalOTHER | 1 | Aug 30, 2013 | clinicaltrials |